Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -47.13%. However, over the past six months, we’ve seen a weaker performance of 23.18%. The price of NTLA leaped by -1.18% over the last 30 days. And in the last five days, it has fallen by -0.22%.
The stock price for Intellia Therapeutics Inc (NTLA) currently stands at $11.35. The stock experienced a substantial increase in the last session, hitting $106.0 after starting at $11.26. The stock’s lowest price was $7.0 before closing at $10.86.
In terms of market performance, Intellia Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $24.16 on 08/23/24, and the lowest value was recorded at $5.90 on 04/07/25.
52-week price history of NTLA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Intellia Therapeutics Inc’s current trading price is -53.04% away from its 52-week high, while its distance from the 52-week low is 92.29%. The stock’s price range during this period has varied between$5.90 and $24.16. The Intellia Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.48 million for the day, a figure considerably lower than their average daily volume of 4.96 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Intellia Therapeutics Inc (NTLA) has experienced a quarterly rise of 36.36% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.22B and boasts a workforce of 403 employees.
Intellia Therapeutics Inc: Analysts’ Ratings Unveiled
As of right now, 18 analysts are rating Intellia Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 9.34, with a change in price of +2.65. Similarly, Intellia Therapeutics Inc recorded 4,457,602 in trading volume during the last 100 days, posting a change of +30.40%.
NTLA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NTLA stands at 0.14. Similarly, the long-term debt-to-equity ratio is also 0.11.
NTLA Stock Stochastic Average
Intellia Therapeutics Inc’s raw stochastic average for the past 50 days is presently 57.24%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 19.18%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 10.19% and 8.19%, respectively.
